Zeitschriftenartikel: „Syndrome d’Usher de type 3“

1

Shah, BelaJ, AshishK Jagati, NileshK Katrodiya, and SonalM Patel. "Griscelli syndrome type-3." Indian Dermatology Online Journal 7, no. 6 (2016): 506. http://dx.doi.org/10.4103/2229-5178.193910.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Gazizova, G. R., M. R. Shaydullina, F. V. Valeeva, and A. I. Galieva. "Autoimmune polyglandular syndrome type 3." Medical Herald of the South of Russia 11, no. 4 (2020): 78–83. http://dx.doi.org/10.21886/2219-8075-2020-11-4-78-83.

Der volle Inhalt der Quelle

Annotation:

Autoimmune polyglandular syndrome type 3 (APS type 3) is a combination of autoimmune thyroid damage in combination with one or more autoimmune endocrine or non-endocrine diseases. It is represented by three subtypes: APS 3A (graves ‘ Disease, or Hashimoto’s thyroiditis and type 1 diabetes mellitus), APS 3B (autoimmune thyroid disease and pernicious anemia), APS 3C (autoimmune thyroid disease and vitiligo, alopecia, and/or other organ-specific autoimmune diseases). Clinical observations of patients with type 3 APS are presented: characteristic clinical syndromes and clinical and laboratory characteristics of patients. These clinical examples demonstrate the importance of thorough examination, alertness and knowledge of endocrinologists about the possibility of developing polyglandular lesions of the endocrine system, the importance of timely prescribed treatment and interdisciplinary interaction of doctors.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Dhankar, Neha, Isha Gupta, Surabhi Dayal, and Sonia Chhabra. "Griscelli syndrome type 3 in siblings." International Journal of Trichology 14, no. 1 (2022): 38. http://dx.doi.org/10.4103/ijt.ijt_42_20.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Pakarinen, L., S. Karjalainen, K. O. J. Simola, P. Laippala, and H. Kaitalo. "Usher's syndrome type 3 in Finland." Laryngoscope 105, no. 6 (1995): 613–17. http://dx.doi.org/10.1288/00005537-199506000-00010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Ruan, Yanfei, Nian Liu, Rong Bai, Silvia G. Priori, and Carlo Napolitano. "Congenital Long QT Syndrome Type 3." Cardiac Electrophysiology Clinics 6, no. 4 (2014): 705–13. http://dx.doi.org/10.1016/j.ccep.2014.07.007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Kahara, Toshio, Hitomi Wakakuri, Juri Takatsuji, et al. "Autoimmune Polyglandular Syndrome Type 3 with Anorexia." Case Reports in Endocrinology 2012 (2012): 1–4. http://dx.doi.org/10.1155/2012/657156.

Der volle Inhalt der Quelle

Annotation:

A 71-year-old man with diabetes mellitus visited our hospital with complaints of anorexia and weight loss (12 kg/3 months). He had megaloblastic anemia, cobalamin level was low, and autoantibody to intrinsic factor was positive. He was treated with intramuscular cyanocobalamin, and he was able to consume meals. GAD autoantibody and ICA were positive, and he was diagnosed with slowly progressive type 1 diabetes mellitus (SPIDDM). Thyroid autoantibodies were positive. According to these findings, he was diagnosed with autoimmune polyglandular syndrome type 3 with SPIDDM, pernicious anemia, and Hashimoto's thyroiditis. Extended periods of cobalamin deficiency can cause serious complications such as ataxia and dementia, and these complications may not be reversible if replacement therapy with cobalamin is delayed. Although type 1 diabetes mellitus with coexisting pernicious anemia is very rare in Japan, physicians should consider the possibility of pernicious anemia when patients with diabetes mellitus have cryptogenic anorexia with the finding of significant macrocytosis (MCV > 100 fL).

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Durongpisitkul, K., and Vymutt J. Gururaj. "Parainfluenza virus type 3 and pertussis syndrome." Indian Journal of Pediatrics 60, no. 1 (1993): 139–42. http://dx.doi.org/10.1007/bf02860523.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kerr, Natalie C., R. Sid Wilroy, and Robert A. Kaufman. "Type 3 Pfeiffer syndrome with normal thumbs." American Journal of Medical Genetics 66, no. 2 (1996): 138–43. http://dx.doi.org/10.1002/(sici)1096-8628(19961211)66:2<138::aid-ajmg3>3.0.co;2-n.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Kaplan, Paige, and Leonhard S. Wolfe. "Sanfilippo syndrome type D." Journal of Pediatrics 110, no. 2 (1987): 267–71. http://dx.doi.org/10.1016/s0022-3476(87)80171-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Kim, Ungsoo Samuel, Joon H. Lee, and Seung-Hee Baek. "Bilateral type 3 Duane retraction syndrome with bilateral tilted disc syndrome." Graefe's Archive for Clinical and Experimental Ophthalmology 251, no. 5 (2012): 1445–46. http://dx.doi.org/10.1007/s00417-012-2122-5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Betterle, Corrado, Silvia Garelli, Graziella Coco, and Patrizia Burra. "A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3)." Autoimmunity Highlights 5, no. 1 (2014): 27–31. http://dx.doi.org/10.1007/s13317-013-0055-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Patni, Nivedita, Abhimanyu Garg, and Chao Xing. "Diet-Responsive Hypercholesterolemia With Cardiofaciocutaneous Syndrome Type 3." Journal of the Endocrine Society 5, Supplement_1 (2021): A308. http://dx.doi.org/10.1210/jendso/bvab048.628.

Der volle Inhalt der Quelle

Annotation:

Abstract Background: Molecular basis of diet responsive hypercholesterolemia remains unclear. We report diet-responsive severe hypercholesterolemia in a young female with cardiofaciocutaneous syndrome type 3 (CFC3) due to a heterozygous pathogenic MAP2K1 variant, suggesting a role of common MAPK variants in LDL-cholesterol (LDL-C) response to diet. Clinical case: A 3-year-old Caucasian female with CFC3 (macrocephaly, frontal bossing, wide nasal root with depressed bridge, anteverted nares, low set fleshy ears, congenital pulmonic valve stenosis, postnatal growth deficiency, hypotonia, and neurocognitive impairment) due to a de novo heterozygous c.389A&gt;G, p.Tyr130Cys pathogenic variant in MAP2K1, presented with extremely elevated serum total cholesterol of 446 mg/dL, triglycerides of 239 mg/dL, HDL-cholesterol of 53 mg/dL, LDL-C of 335 mg/dL (normal range &lt; 110 mg/dL) and serum apolipoprotein B level 219 mg/dL (normal range &lt; 90 mg/dL). Her LDL-C was 252 mg/dL a year ago and 215 mg/dL one month prior to presentation. Reducing total dietary fat to 20–25% of total energy and saturated fat to &lt;6% of total energy over the next 4 months lowered LDL-C to 104 mg/dL. However, her weight decreased by 0.5 kg and liberalization of fat intake again increased LDL-C to 222 mg/dL. Her father has mildly elevated LDL-C of 160 mg/dL and her mother had normal LDL-C of 80 mg/dL. Her plasma phytosterol levels were normal and she had ApoE3/E3 genotype. Targeted genetic testing of the patient and parents showed a benign heterozygous LDL receptor (LDLR) variant c.2242G&gt;A; p.Asp748Asn, (Minor allele frequency 0.00008) in the patient and her father. Whole exome sequencing of the patient and both parents showed no known disease-causing variants in LDLR, APOB, PCSK9, LDLRAP1, APOE, STAP1, LIPA, ABCG5, ABCG8 and other known hyperlipidemia-related genes. There are no previous reports of hypercholesterolemia in patients with CFC3. MAP2K1 stimulates various MAP kinases upon wide variety of extra- and intracellular signal and is involved in cell proliferation, differentiation, transcription regulation and development. Previous studies of the relationship between p42/44MAPK activation and LDLR expression in human hepatoma HepG2-derived cell line showed that that activation of the Raf-1/MEK/p42/44MAPK cascade induces LDLR expression and modulation of the Raf-1 kinase signal strength can determine LDLR expression levels. Thus, extent of MAPK activation can alter signaling of LDLR, resulting in hypercholesterolemia. Conclusion: Our case report suggests that MAP2K1 may play a significant role in LDLR signaling, and some MAP2K1 variants may be associated with diet-responsive hypercholesterolemia. Larger studies are required to assess dietary response to LDL-C in subjects with MAP2K1 variants.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Drubel, Kim, Benedikt Marahrens, Oliver Ritter, and Daniel Patschan. "Kidney-Related Outcome in Cardiorenal Syndrome Type 3." International Journal of Nephrology 2022 (February 7, 2022): 1–9. http://dx.doi.org/10.1155/2022/4895434.

Der volle Inhalt der Quelle

Annotation:

Background and Aim. In cardiorenal syndrome (CRS) type 3, acute kidney injury (AKI) induces and, sometimes, even perpetuates acute cardiac pathologies such as arrhythmias with or without cardiac decompensation or the latter due to other causes. Epidemiological data on CRS type 3 are limited. The aim of this study was to analyze epidemiological and outcome variables in CRS type 3. Methods. A single-center, retrospective and observational trial. All subjects with positive AKI alert, treated at the University Hospital Brandenburg between January and December 2019, were evaluated. Definition of CRS type 3 was according to predefined criteria. The three endpoint categories were in-hospital death, dialysis, and recovery of kidney function. Results. A total number of 1,334 AKI alerts were screened. Finally, 95 subjects received the diagnosis CRS type 3. The survival rates were 47.1% (females) and 43.6% (males). 46.8% of affected females and 33.3% of the males required dialysis therapy. Complete recovery at the time of discharge occurred in 35.8%, and no recovery at all was found in 54.7%. Conclusions. All three predefined study endpoints, the mortality, the prevalence of dialysis, and the percentage of subjects without recovery of kidney function, were notably high. Therefore, AKI patients with imminent or established cardiac complications require the highest attention of nephrologists in charge.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Cook, Susan A., Gayle B. Collin, Roderick T. Bronson, et al. "A Mouse Model for Meckel Syndrome Type 3." Journal of the American Society of Nephrology 20, no. 4 (2009): 753–64. http://dx.doi.org/10.1681/asn.2008040412.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Wilde, Arthur A. M., Arthur J. Moss, Elizabeth S. Kaufman, et al. "Clinical Aspects of Type 3 Long-QT Syndrome." Circulation 134, no. 12 (2016): 872–82. http://dx.doi.org/10.1161/circulationaha.116.021823.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Dash, Sananta Kumar, Sudha Kansal, Rakesh Sharma, Devender Kumar Agrawal, and Harsh Dua. "Acquired hemophilia complicated by cardiorenal syndrome type 3." Indian Journal of Critical Care Medicine 17, no. 6 (2013): 378–81. http://dx.doi.org/10.4103/0972-5229.123456.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Nishizaki, Naoto, Shuichiro Fujinaga, Daishi Hirano, et al. "Membranoproliferative glomerulonephritis Type 3 associated with Kabuki syndrome." Clinical Nephrology 81, no. 05 (2014): 369–73. http://dx.doi.org/10.5414/cn107464.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Tsilou, Ekaterini T., Benjamin I. Rubin, George F. Reed, et al. "Milder ocular findings in Hermansky–Pudlak syndrome type 3 compared with Hermansky–Pudlak syndrome type 1." Ophthalmology 111, no. 8 (2004): 1599–603. http://dx.doi.org/10.1016/j.ophtha.2003.12.058.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Postema, Pieter G., and Raymond L. Woosley. "Use of Drugs in Long QT Syndrome Type 3 and Brugada Syndrome." Cardiac Electrophysiology Clinics 6, no. 4 (2014): 811–17. http://dx.doi.org/10.1016/j.ccep.2014.08.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Akgun, Ozlem, Ceyhan Altun, Gunseli Polat, and Ceren Yildirim. "Oral and dental findings of Griscelli syndrome type 3." Archives of Clinical and Experimental Surgery (ACES) 4, no. 3 (2015): 164. http://dx.doi.org/10.5455/aces.20130226034218.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Horino, Taro, Masami Ogasawara, Osamu Ichii, and Yoshio Terada. "Autoimmune polyglandular syndrome type 3 variant in rheumatoid arthritis." Romanian Journal of Internal Medicine 58, no. 1 (2020): 40–43. http://dx.doi.org/10.2478/rjim-2019-0024.

Der volle Inhalt der Quelle

Annotation:

AbstractIntroduction. Although type 1 diabetes mellitus is largely associated with autoimmune thyroid disease and this entity has been recently referred to as autoimmune polyglandular syndrome type 3 variant, the autoimmune polyglandular syndrome type 3 variant in patients with rheumatoid arthritis has not been reported so far. We herein describe the first case of rheumatoid arthritis that was associated with autoimmune polyglandular syndrome type 3 variant.Case report. A 77-year-old woman with a 15-year history of rheumatoid arthritis (RA) and a 10-year history of type 2 diabetes mellitus (T2D) presented with polyarthralgia and hyperglycaemia. Methotrexate 16 mg/week had been started from the onset and was continued, and adalimumab 40 mg/day was started for RA. Insulin treatment was also started for the diabetes. Laboratory examinations revealed high levels of C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide antibody, and matrix metalloprotease 3. She was admitted multiple times as the symptoms recurred after treatment. Subsequently, based on the clinical course and investigations, she was diagnosed with type 1 diabetes mellitus and Graves’ disease occurring during the course of RA and T2D. Her clinical course improved after reinforcement of insulin therapy and the addition of thiamazole therapy.Conclusion. In patients with rheumatoid arthritis, the autoimmune polyglandular syndrome type 3 variant should be considered as the cause of the deterioration.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Otsubo, Yuto, Yuji Kano, Hiroshi Suzumura, and Shigemi Yoshihara. "Type 3 antenatal Bartter syndrome presenting with mild polyuria." BMJ Case Reports 14, no. 4 (2021): e242086. http://dx.doi.org/10.1136/bcr-2021-242086.

Der volle Inhalt der Quelle

Annotation:

Bartter syndrome (BS) is a well-recognised inherited tubular dysfunction that causes polyuria, metabolic alkalosis and hypokalaemia. Among BS cases, antenatal/neonatal BS (ABS) usually shows distinct polyhydramnios prenatally and presents features of BS in the early neonatal period. We encountered a premature infant with type 3 ABS presenting with mild polyuria and discuss the pathogenesis of mild polyuria in type 3 ABS. A male infant was born at 31 weeks’ gestation. His mother received amniocentesis because of polyhydramnios. Hyponatraemia and hypokalaemia appeared within 3 days after birth. Metabolic alkalosis, hyperreninaemia and hyperaldosteronism were also identified. Temporary polyuria developed at 1 month after birth; however, the mean urine output during hospitalisation was within the normal range. CLCNKB compound heterozygous mutations were confirmed. Polyuria of type 3 ABS may be less severe than in other types of ABS. Lower urine sodium loss may be a characteristic feature of type 3 ABS.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Benkhaira, N., N. Kerouaz, and Y. Kitouni. "Syndrome de Cockayne type 3 ; à propos d’un cas." La Revue de Médecine Interne 42 (December 2021): A420. http://dx.doi.org/10.1016/j.revmed.2021.10.142.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Sharma, Somya, VivekKumar Dey, Animesh Saxena, and Anil Gour. "Griscelli syndrome Type 3 in three non-identical siblings." Journal of Mahatma Gandhi Institute of Medical Sciences 26, no. 1 (2021): 63. http://dx.doi.org/10.4103/jmgims.jmgims_35_19.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Seys, Elsa, Olga Andrini, Mathilde Keck, et al. "Clinical and Genetic Spectrum of Bartter Syndrome Type 3." Journal of the American Society of Nephrology 28, no. 8 (2017): 2540–52. http://dx.doi.org/10.1681/asn.2016101057.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Alcid, Joel, Jeffrey Kim, David Bruni, and Ibiyonu Lawrence. "A Rare Case of Hermansky-Pudlak Syndrome Type 3." Journal of Hematology 7, no. 2 (2018): 76–78. http://dx.doi.org/10.14740/jh387w.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

KAUFMAN, ELIZABETH S. "Use of Ranolazine in Long-QT Syndrome Type 3." Journal of Cardiovascular Electrophysiology 19, no. 12 (2008): 1294–95. http://dx.doi.org/10.1111/j.1540-8167.2008.01255.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Brookler, Kenneth H. "Electronystagmography in Ménière's Syndrome: Type 3 Simultaneous Binaural Bithermal." Ear, Nose & Throat Journal 79, no. 10 (2000): 767. http://dx.doi.org/10.1177/014556130007901004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Dittmar, Manuela, and George J. Kahaly. "Genetics of the Autoimmune Polyglandular Syndrome Type 3 Variant." Thyroid 20, no. 7 (2010): 737–43. http://dx.doi.org/10.1089/thy.2010.1639.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Quintos, JB, Monica Grover, Charlotte M. Boney, and Max Salas. "Autoimmune polyglandular syndrome Type 3 and growth hormone deficiency." Pediatric Diabetes 11, no. 6 (2010): 438–42. http://dx.doi.org/10.1111/j.1399-5448.2009.00622.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Chuasuwan, Anan, and John A. Kellum. "Cardio-Renal Syndrome Type 3: Epidemiology, Pathophysiology, and Treatment." Seminars in Nephrology 32, no. 1 (2012): 31–39. http://dx.doi.org/10.1016/j.semnephrol.2011.11.005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Kunz, Robert, and Russell Valentine. "Marfan's Syndrome Presenting as a Type 3 Aortic Dissection." Chest 88, no. 3 (1985): 463–65. http://dx.doi.org/10.1378/chest.88.3.463.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Colussi, Giacomo, Maria Elisabetta De Ferrari, Silvana Tedeschi, Silvia Prandoni, Marie Louise Syrén, and Giovanni Civati. "Bartter syndrome type 3: an unusual cause of nephrolithiasis." Nephrology Dialysis Transplantation 17, no. 3 (2002): 521–23. http://dx.doi.org/10.1093/ndt/17.3.521.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Lamey, P. J., A. B. Lamb, A. Hughes, K. A. Milligan, and A. Forsyth. "Type 3 burning mouth syndrome: psychological and allergic aspects." Journal of Oral Pathology and Medicine 23, no. 5 (1994): 216–19. http://dx.doi.org/10.1111/j.1600-0714.1994.tb01116.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Clementi, Anna, Grazia Maria Virzì, Alessandra Brocca, et al. "Advances in the Pathogenesis of Cardiorenal Syndrome Type 3." Oxidative Medicine and Cellular Longevity 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/148082.

Der volle Inhalt der Quelle

Annotation:

Cardiorenal syndrome (CRS) type 3 is a subclassification of the CRS whereby an episode of acute kidney injury (AKI) leads to the development of acute cardiac injury or dysfunction. In general, there is limited understanding of the pathophysiologic mechanisms involved in CRS type 3. An episode of AKI may have effects that depend on the severity and duration of AKI and that both directly and indirectly predispose to an acute cardiac event. Experimental data suggest that cardiac dysfunction may be related to immune system activation, inflammatory mediators release, oxidative stress, and cellular apoptosis which are well documented in the setting of AKI. Moreover, significant derangements, such as fluid and electrolyte imbalance, metabolic acidosis, and uremia, which are typical features of acute kidney injury, may impair cardiac function. In this review, we will focus on multiple factors possibly involved in the pathogenesis issues regarding CRS type 3.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Shimomura, Hiroko, Yukiho Nakase, Hiroto Furuta, et al. "A rare case of autoimmune polyglandular syndrome type 3." Diabetes Research and Clinical Practice 61, no. 2 (2003): 103–8. http://dx.doi.org/10.1016/s0168-8227(03)00115-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Ahmed, Saeed, Supawat Ratanapo, Saira Rashid, Wisit Cheungpasitporn, Edward F. Bischof, and Jesse P. Cone. "Syncope in Brugada syndrome type 3: an electrocardiographic lesson." American Journal of Emergency Medicine 31, no. 3 (2013): 621–22. http://dx.doi.org/10.1016/j.ajem.2012.11.016.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Kassem Youssef, H., C. Ramstein, E. Ginglinger, F. Chouta Ngaha, H. Nojavan, and C. Michel. "Syndrome de Griscelli de type 3 : un nouveau cas." Annales de Dermatologie et de Vénéréologie 145, no. 12 (2018): 785–89. http://dx.doi.org/10.1016/j.annder.2018.07.030.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Neres-Santos, Raquel Silva, Giovana Marchini Armentano, Jéssica Verônica da Silva, Carlos Alexandre Falconi, and Marcela Sorelli Carneiro-Ramos. "Progress and Challenges of Understanding Cardiorenal Syndrome Type 3." Reviews in Cardiovascular Medicine 24, no. 1 (2023): 8. http://dx.doi.org/10.31083/j.rcm2401008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Pérez-Riera, Andrés Ricardo, Raimundo Barbosa-Barros, Rodrigo Daminello Raimundo, Marianne Penachini da Costa de Rezende Barbosa, Isabel Cristina Esposito Sorpreso, and Luiz Carlos de Abreu. "The congenital long QT syndrome Type 3: An update." Indian Pacing and Electrophysiology Journal 18, no. 1 (2018): 25–35. http://dx.doi.org/10.1016/j.ipej.2017.10.011.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Kumru, Pınar, Nurettin Aka, Gültekin Köse, Zeynep Tuzcular Vural, Önder Peker, and Hülya Kayserili. "Short Rib Polydactyly Syndrome Type 3 with Absence of Fibulae (Verma-Naumoff Syndrome)." Fetal Diagnosis and Therapy 20, no. 5 (2005): 410–14. http://dx.doi.org/10.1159/000086822.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Taous, Abdellah, Taoufik Boubga, Maha Ait Berri, Jalal El benaye, Ali Zinebi, and Tarik Boulahri. "Neuropsychiatric Disorders Revealing Autoimmune Polyendocrine Syndrome Type 3: Case Report." Scholars Journal of Medical Case Reports 11, no. 10 (2023): 1781–83. http://dx.doi.org/10.36347/sjmcr.2023.v11i10.015.

Der volle Inhalt der Quelle

Annotation:

Multiple autoimmune syndrome is a rare pathological condition because it associates at least three different autoimmune diseases in the same patient. We discuss through this case and with a review of the literature MAS type 3 and its association with neuroanemic syndrome which remains exceptional. This is a 47-year-old patient, followed for vitiligo and a depressive syndrome, admitted for an ataxic gait lasting a month, in whom the neurological examination revealed a combined sclerosis syndrome of the spinal cord associated with a static cerebellar syndrome. Dermatological examination revealed diffuse acrofacial vitiligo. The biological assessment revealed Biermer's anemia and autoimmune thyroiditis. The clinical evolution was favorable under treatment. The discovery of Biermer's disease in a woman should prompt the search for arguments for one or other associated autoimmune diseases.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Vinay, S. "P60 Family with type 1 Stickler syndrome." Indian Journal of Rheumatology 3, no. 3 (2008): S43. http://dx.doi.org/10.1016/s0973-3698(10)60504-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Ozer Sensoy, Nur, Suleybe Elvan Zafer, Isa Kilic, Haydar Durak, Nizameddin Koca, and Yavuz Ayar. "Coexistence of Hemolytic Uremic Syndrome and Type 3 Cardiorenal Syndrome Due to Weil’s Disease." Turkish Journal of Nephrology 32, no. 2 (2023): 168–69. http://dx.doi.org/10.5152/turkjnephrol.2023.22154458.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Patschan, Daniel, Benedikt Marahrens, Monique Jansch, Susann Patschan, and Oliver Ritter. "Experimental Cardiorenal Syndrome Type 3: What Is Known so Far?" Journal of Clinical Medicine Research 14, no. 1 (2022): 22–27. http://dx.doi.org/10.14740/jocmr4639.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Tatu, A. "Multiple Autoimmune Syndrome type 3- Thyroiditis, Vitiligo and Alopecia Areata." Acta Endocrinologica (Bucharest) 13, no. 1 (2017): 124–25. http://dx.doi.org/10.4183/aeb.2017.124.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Masuda, Saeko, Masahiro Mori, Shinsuke Hamada, Hiroki Masuda, Akiyuki Uzawa, and Satoshi Kuwabara. "Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient." Clinical and Experimental Neuroimmunology 6, no. 3 (2015): 299–303. http://dx.doi.org/10.1111/cen3.12232.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Chorin, Ehud, Rivki Taub, Aron Medina, Nir Flint, Sami Viskin, and Jesaia Benhorin. "Long-term flecainide therapy in type 3 long QT syndrome." EP Europace 20, no. 2 (2017): 370–76. http://dx.doi.org/10.1093/europace/euw439.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Wilde, Arthur A. M., and Carol Ann Remme. "Therapeutic approaches for Long QT syndrome type 3: an update." EP Europace 20, no. 2 (2017): 222–24. http://dx.doi.org/10.1093/europace/eux039.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Cornel, E., R. De Wit, and E. Van Haarst. "372Biofeedback physical therapy for chronic pelvic pain syndrome type 3." European Urology Supplements 4, no. 3 (2005): 95. http://dx.doi.org/10.1016/s1569-9056(05)80378-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zeitschriftenartikel zum Thema „Syndrome d’Usher de type 3“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an